171 related articles for article (PubMed ID: 24516999)
1. Screening of commercial cyclic peptides as inhibitor envelope protein dengue virus (DENV) through molecular docking and molecular dynamics.
Parikesit AA; Kinanty ; Tambunan US
Pak J Biol Sci; 2013 Dec; 16(24):1836-48. PubMed ID: 24516999
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent Inhibitors for the Inhibition of Dengue Envelope Protein: An In Silico Approach.
Aarthy M; Singh SK
Curr Top Med Chem; 2018; 18(18):1585-1602. PubMed ID: 30360716
[TBL] [Abstract][Full Text] [Related]
3. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection.
Panya A; Sawasdee N; Junking M; Srisawat C; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus.
Anasir MI; Ramanathan B; Poh CL
Viruses; 2020 Mar; 12(4):. PubMed ID: 32225021
[TBL] [Abstract][Full Text] [Related]
5. Conformational and energy evaluations of novel peptides binding to dengue virus envelope protein.
Amir-Hassan A; Lee VS; Baharuddin A; Othman S; Xu Y; Huang M; Yusof R; Rahman NA; Othman R
J Mol Graph Model; 2017 Jun; 74():273-287. PubMed ID: 28458006
[TBL] [Abstract][Full Text] [Related]
6. Identification of sequence motifs involved in Dengue virus-host interactions.
Asnet Mary J; Paramasivan R; Shenbagarathai R
J Biomol Struct Dyn; 2016; 34(3):676-87. PubMed ID: 25905427
[TBL] [Abstract][Full Text] [Related]
7. Peptide inhibitors against dengue virus infection.
Panya A; Bangphoomi K; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2014 Aug; 84(2):148-57. PubMed ID: 24612829
[TBL] [Abstract][Full Text] [Related]
8. Screening of commercial cyclic peptide conjugated to HIV-1 Tat peptide as inhibitor of N-terminal heptad repeat glycoprotein-2 ectodomain Ebola virus through in silico analysis.
Tambunan USF; Alkaff AH; Nasution MAF; Parikesit AA; Kerami D
J Mol Graph Model; 2017 Jun; 74():366-378. PubMed ID: 28482272
[TBL] [Abstract][Full Text] [Related]
9. Discovery and design of cyclic peptides as dengue virus inhibitors through structure-based molecular docking.
Idrees S; Ashfaq UA
Asian Pac J Trop Med; 2014 Jul; 7(7):513-6. PubMed ID: 25063278
[TBL] [Abstract][Full Text] [Related]
10. Epitopes based drug design for dengue virus envelope protein: A computational approach.
Wadood A; Mehmood A; Khan H; Ilyas M; Ahmad A; Alarjah M; Abu-Izneid T
Comput Biol Chem; 2017 Dec; 71():152-160. PubMed ID: 29096381
[TBL] [Abstract][Full Text] [Related]
11. Targeting domain-III hinging of dengue envelope (DENV-2) protein by MD simulations, docking and free energy calculations.
Dubey KD; Tiwari G; Ojha RP
J Mol Model; 2017 Apr; 23(4):102. PubMed ID: 28255859
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.
Takagi Y; Matsui K; Nobori H; Maeda H; Sato A; Kurosu T; Orba Y; Sawa H; Hattori K; Higashino K; Numata Y; Yoshida Y
Bioorg Med Chem Lett; 2017 Aug; 27(15):3586-3590. PubMed ID: 28539222
[TBL] [Abstract][Full Text] [Related]
13. Dynamics and binding interactions of peptide inhibitors of dengue virus entry.
Isa DM; Chin SP; Chong WL; Zain SM; Rahman NA; Lee VS
J Biol Phys; 2019 Mar; 45(1):63-76. PubMed ID: 30680580
[TBL] [Abstract][Full Text] [Related]
14. In silico design of peptide inhibitors for Dengue virus to treat Dengue virus-associated infections.
Ajmal A; Shahab M; Waqas M; Zheng G; Zulfat M; Bin Jardan YA; Wondmie GF; Bourhia M; Ali I
Sci Rep; 2024 Jun; 14(1):13130. PubMed ID: 38849372
[TBL] [Abstract][Full Text] [Related]
15. Receptor-Guided De Novo Design of Dengue Envelope Protein Inhibitors.
Desai VH; Kumar SP; Pandya HA; Solanki HA
Appl Biochem Biotechnol; 2015 Oct; 177(4):861-78. PubMed ID: 26299376
[TBL] [Abstract][Full Text] [Related]
16. Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication.
Abdul Ahmad SA; Palanisamy UD; Tejo BA; Chew MF; Tham HW; Syed Hassan S
Virol J; 2017 Nov; 14(1):229. PubMed ID: 29162124
[TBL] [Abstract][Full Text] [Related]
17. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.
Mirza SB; Lee RCH; Chu JJH; Salmas RE; Mavromoustakos T; Durdagi S
J Mol Graph Model; 2018 Jan; 79():88-102. PubMed ID: 29156382
[TBL] [Abstract][Full Text] [Related]
18. A novel flavanone derivative inhibits dengue virus fusion and infectivity.
Srivarangkul P; Yuttithamnon W; Suroengrit A; Pankaew S; Hengphasatporn K; Rungrotmongkol T; Phuwapraisirisan P; Ruxrungtham K; Boonyasuppayakorn S
Antiviral Res; 2018 Mar; 151():27-38. PubMed ID: 29360474
[TBL] [Abstract][Full Text] [Related]
19. Anti-dengue virus activity of scytovirin and evaluation of point mutation effects by molecular dynamics and binding free energy calculations.
Siqueira AS; Jerônimo Lima AR; de Souza RC; Santos AS; da Silva Gonçalves Vianez Júnior JL; Gonçalves EC
Biochem Biophys Res Commun; 2017 Aug; 490(3):1033-1038. PubMed ID: 28666874
[TBL] [Abstract][Full Text] [Related]
20. Structure-based screening and validation of potential dengue virus inhibitors through classical and QM/MM affinity estimation.
Ahmed M; Kumar A; Hobman TC; Barakat K
J Mol Graph Model; 2019 Jul; 90():128-143. PubMed ID: 31082639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
